similar ivl track ahead expec
emerg sign coronari expans btk
interest exist use multipl
underappreci vessel bed cfa iliac
momentum continu shockwav still earli stage
commerci deliv sale vs mse driven
quicken pace commerci roll-out broad traction us atk ex
us coronari us sale beat mse physician uptak
broad knee atk intervent build traction
larger cfa iliac vessel note shockwav saw limit benefit
paclitaxel mortal concern see ex us growth driven
coronari sale ivl safety/efficaci profil valu reson physician
drive address expans share gain earli traction
cathet knee btk continu broader roll-out expect
viva novemb note btk roll-out growth
roll-out us growth key driver
growth shockwav discuss initi see
line expect opex beat mse
driven stall trial restart come
month discuss pleas see exhibit reconcili result vs
guidanc look somewhat conserv shockwav rais sale
high end previou rang
high end beat increas sale
high end guidanc commentari suggest sale line
model q/q growth respect
look meager q/q growth prior three quarter reflect
ex us season coronari strong deeper ivl adopt
across vessel bed broader btk launch drive
substanti growth rais sale estim
prior pleas see exhibit total list model chang
multipl catalyst horizon near term stori driven commerci
execut manag drive util current center roll
cathet new center cathet btk next key catalyst
limit releas acceler cours year broadli
launch viva novemb along two smaller cathet
suit smaller btk vessel trial resum later year
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
follow paclitaxel fda panel recommend data
registri tct septemb driver util coronari
continu enrol timelin data remain unchang
larg bore peripher cathet lx still track launch
shockwav may increas function devic subsequ gener
remain equal-weight valuat pad/cad larg market shockwav
disrupt technolog pois rapid adopt clear investor look
farther futur given signific perform stock sinc ipo
suggest greater comfort market develop physician adopt
remain equal-weight driven valuat reflect balanc pictur
signific opportun risk pt base base case
sale support ev sale discount
dcf assum long term vessel bed penetr world-wide
oper margin wacc view could chang given
potenti technolog pend increment dilig suggest faster
assum adopt ivl greater longer term util increment
data point derisk commerci execut clinic risk shockwav
tripl sale infrastructur next pad cad
data posit first-in-man data tavl
shockwav adopt driven ivl valu proposit larg cad/pad
shockwav adopt driven
ivl valu proposit larg cad/pad
price target reflect multipl
base case sale high growth smid cap devic
compani support dcf valuat assum wacc
penetr atk btk coronari vessel bed
assum sale grow compound-annual-growth-rate driven
ivl differenti clinic econom valu proposit
shockwav momentum inflect faster expect sale expect
revis higher relaunch begin contribut sale growth
larg bore adopt drive broader util atk ahead expect
gain broad traction europ despit limit reimburs suggest fast
ramp us launch reimburs less concern valuat
multipl expand given longer term expect multibillion dollar market
ev/sal support dcf
ev/sal support dcf
shockwav begin drive market adopt ivl given eas use abil
treat hard reach calcium better peer safeti profil
relaunch btk show sign traction broader adopt
coronari cathet continu gain traction europ
atk cathet adopt larg bore tavr/impella procedur
reimburs ev/sal multipl peer group justifi
shockwav peer growth prospect
physician adopt expect sale revis lower
reimburs prove greater concern especi europ light limit
longer term data limit adopt valuat multipl contract still
repres larg multibillion dollar longer term growth prospect
ivl
shockwav provid ivl cathet
cad pad market
compani differenti offer given
eas use abil treat calcium
safeti profil posit compani
drive adopt multipl vessel bed
estim impli msd penetr
intermedi term risk adjust
earli stage commerci
reimburs suffici vessel bed
ivl key valu proposit
notabl coronari btk larg bore
relaunch drive
ww sale growth us launch drive
ww sale growth
bp us vessel bed penetr
impli addit dcf valu
pad cad data drive physician
adopt possibl guidelin discuss
gross margin doubl
lx cathet updat expect
risk achiev price
channel develop occur faster
slower pace physician adopt
less limit lead greater lower vessel
cad data posit delay us
reimburs prove less
rate limit util expect
patent litig csi result
million except ep
chang net work capit
pv free flow
growth work capit
perpetu growth rate
equiti
after-tax cost debt
total discount valu
discount valu nol
sale
sale
sale
sale
sale
sale
dollar million except per share data
dollar million except per share data
dollar million except per share data
invest
st debt current portion lt debt
dollar million except per share data
net chang work capit
sale purchas invest
net invest
chg short-term debt
chg long-term debt
chang equiti
net financ
begin period
end period
